An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Phillips, Patrick P J ^a   Fielding, Katherine ^b   Nunn, Andrew J ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

AFRICA; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; ETHNICITY; HONG KONG; HUMAN; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULOSIS;

BIOLOGICAL MARKERS; CELL CULTURE TECHNIQUES; CLINICAL TRIALS, PHASE III AS TOPIC; ENDPOINT DETERMINATION; HUMANS; LINEAR MODELS; SPUTUM; TUBERCULOSIS;

EID: 84877309715     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063840     Document Type: Article

References (46)

1. Youmans GP (1979) Tuberculosis. Philadelphia: W. B. Saunders.
2. World Health Organization (2011) Global tuberculosis control 2011. Geneva.
3. Fox W, Ellard GA, Mitchison DA, (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3: S231-S279.
4. Karim SSA, Churchyard GJ, Karim QA, Lawn SD, (2009) HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 374: 921-933.
5. Merle CS, Sismanidis C, Bah Sow O, Gninafon M, Horton J, et al. (2012) A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project. Trials 13: 61.
6. Biomarker Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95.
7. Prentice RL, (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8: 431-440.
8. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, et al. (2011) CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med 184: 972-979.
9. Baker SG, Kramer BS (2003) A perfect correlate does not a surrogate make. BMC Med Res Methodol 3: 16. Epub 2003 Sep 2009.
10. Perrin FMR, Lipman MCI, McHugh TD, Gillespie SH, (2007) Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect Dis 7: 481-490.
11. Nahid P, Saukkonen J, Mac Kenzie W, Johnson JL, Phillips PJ, et al. (2011) Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap. Am J Respir Crit Care Med.
12. Wallis RS, (2007) Surrogate markers to assess new therapies for drug-resistant tuberculosis. Expert Rev Anti Infect Ther 5: 163-168.
13. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, et al. (2002) Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360: 528-534.
14. Aber VR, Nunn AJ, (1978) Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy. Bull Int Union Tuberc 53: 276-280.
15. Mitchison DA, (1996) Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. Soc Appl Bacteriol Symp Ser 25: 72S-80S.
16. Mitchison DA, (1993) Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 147: 1062-1063.
17. Zumla A, Wallis R, Doherty M, Klein N, Parida S, et al. (2008) Joint TDR/EC expert consultation on biomarkers in tuberculosis: Report of the joint TDR/EC expert consultation to evaluate the potential roles of biomarkers in the management of HIV-infected and HIV-uninfected patients with tuberculosis. Geneva.
18. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, et al. (2010) Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 10: 387-394.
19. Christie DA, Tansey EM (2005) Short-Course Chemotherapy for Tuberculosis: The transcript of a witness seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, 3rd Febuary 2004.editor: Wellcome Trust Centre for the History of Medicine at UCL.
20. D'Esopo ND, (1982) Clinical trials in pulmonary tuberculosis. Am Rev Respir Dis 125: 85-93.
21. Nunn AJ, Phillips PPJ, Gillespie SH, (2008) Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis 88: S85-S92.
22. Phillips PP, Nunn AJ, (2010) Challenges of Phase III study design for trials of new drug regimens for the treatment of TB. Future Medicinal Chemistry 2: 1273-1282 (1210).
23. Daniels MJ, Hughes MD, (1997) Meta-analysis for the evaluation of potential surrogate markers. Stat Med 16: 1965-1982.
24. Burzykowski T, Molenberghs G, Buyse ME (2005) The Evaluation of Surrogate Endpoints. New York: Springer.
25. Global Alliance for TB Drug Development (2001) Tuberculosis. Scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb) 81Suppl 1: 1-52.
26. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, et al. (2000) A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 45: 859-870.
27. Spigelman MK, (2007) New tuberculosis therapeutics: a growing pipeline. J Infect Dis 196Suppl 1: S28-S34.
28. Wang JY, Wang JT, Tsai TH, Hsu CL, Yu CJ, et al. (2010) Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis 14: 65-71.
29. Mac Kenzie WR, Heilig CM, Bozeman L, Johnson JL, Muzanye G, et al. (2011) Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One 6: e18358.
30. Burman WJ, Bliven EE, Cowan L, Bozeman L, Nahid P, et al. (2009) Relapse associated with active disease caused by Beijing strain of Mycobacterium tuberculosis. Emerg Infect Dis 15: 1061-1067.
31. Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, et al. (2010) Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One 5: e10753.
32. Davies GR, (2010) Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. Tuberculosis (Edinb) 90: 171-176.
33. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, et al. (2008) A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12: 128-138 (111).
34. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, et al. (2009) Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis. Am J Respir Crit Care Med 180: 273-280.
35. Phillips PP, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, et al. (2012) Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis. J Infect Dis.
36. Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M, et al. (2010) Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infectious Diseases 10: 68-69.
37. Chaisson RE, Churchyard GJ, (2010) Recurrent tuberculosis: relapse, reinfection, and HIV. J Infect Dis 201: 653-655.
38. Lambert M-L, Hasker E, Deun AV, Roberfroid D, Boelaert M, et al. (2003) Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis 3: 282-287.
39. Jindani A, Nunn AJ, Enarson DA, (2004) Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 364: 1244-1251.
40. Honeyborne I, McHugh TD, Phillips PP, Bannoo S, Bateson A, et al. (2011) Molecular Bacterial Load Assay, a Culture-Free Biomarker for Rapid and Accurate Quantification of Sputum Mycobacterium tuberculosis Bacillary Load during Treatment. J Clin Microbiol 49: 3905-3911.
41. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR, (2010) Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. Am J Respir Crit Care Med 181: 174-180.
42. Blakemore R, Nabeta P, Davidow AL, Vadwai V, Tahirli R, et al. (2011) A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. Am J Respir Crit Care Med 184: 1076-1084.
43. Rachow A, Zumla A, Heinrich N, Rojas-Ponce G, Mtafya B, et al. (2011) Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay-a clinical validation study. PLoS One 6: e20458.
44. East and Central African/British Medical Research Council (1983) Controlled clinical trial of 4 short-couse regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Tubercle 64: 153-166.
45. Madras Tuberculosis Chemotherapy Centre (1960) A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India. Bull WHO 23: 535-585.
46. Simon G, (1966) Radiology in epidemiological studies and some therapeutic trials. British Medical Journal 2: 491.